Press Releases April 29, 2026 04:30 PM

Toll Brothers to Webcast Its Second Quarter 2026 Earnings Conference Call Live on May 20, 2026 at 8:30 a.m. (ET)

Toll Brothers announces webcast for Q2 2026 earnings call scheduled for May 20, 2026.

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
TOL

Toll Brothers, a leading luxury home builder listed on the NYSE as TOL, will webcast its second quarter fiscal 2026 earnings conference call live on May 20, 2026. The company will announce its financial results after market close on May 19. The call will be hosted by the Executive Chairman and CEO and accessible via the company’s investor relations website.

Toll Brothers to Webcast Its Second Quarter 2026 Earnings Conference Call Live on May 20, 2026 at 8:30 a.m. (ET)
TOL
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Toll Brothers will report Q2 FY2026 earnings on May 19, with a live webcast for investors on May 20.
  • The company is a leading luxury home builder operating in over 60 U.S. markets, serving multiple buyer segments.
  • They have won multiple industry awards demonstrating leadership and strong brand recognition in the homebuilding sector.

FORT WASHINGTON, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, will broadcast live on its website, www.TollBrothers.com, a conference call to discuss results for its second quarter ended April 30, 2026. The call is scheduled for 8:30 a.m. (ET) on Wednesday, May 20, 2026. The call will be hosted by Douglas C. Yearley, Jr., Executive Chairman of the Board, and Karl K. Mistry, Chief Executive Officer. The Company will announce its second quarter FY 2026 results after the market close on Tuesday, May 19, 2026.

The call can be accessed through the Investor Relations section of the Toll Brothers website, www.TollBrothers.com. To hear the call, visit the Toll Brothers website, then click on the Investor Relations page, and select “Events & Presentations.” The call can be heard live or through an online replay which will follow.

About Toll Brothers
Toll Brothers, Inc., a Fortune 500 Company, is the nation’s leading builder of luxury homes. The Company was founded in 1967 and became a public company in 1986 with common stock listed on the New York Stock Exchange under the symbol “TOL.” Toll Brothers builds new homes and communities in over 60 markets across the United States, serving first-time, move-up, active-adult, and second-home buyers. The Company also operates its own architectural, engineering, mortgage, title, land development, smart home technology, landscape, and building components manufacturing businesses. 

Toll Brothers was named the #1 Most Admired Home Builder in Fortune magazine’s 2026 list of the World’s Most Admired Companies®, the ninth year the Company has achieved this honor. Toll Brothers has also been named Builder of the Year by Builder magazine and is the first two-time recipient of Builder of the Year from Professional Builder magazine. For more information visit TollBrothers.com. 

From Fortune, ©2026 Fortune Media IP Limited. All rights reserved. Used under license. 

INVESTOR CONTACT: 
Gregg Ziegler (215) 938-8365
gziegler@tollbrothers.com

MEDIA CONTACT:
Heather Reeves (215) 328-7634
hreeves@tollbrothers.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2c8ebdf4-7376-47ed-a33e-5c0456e27bb9


Risks

  • Financial results could underperform expectations impacting stock price and investor confidence, affecting the construction and real estate sectors.
  • Market demand fluctuations in the luxury housing market due to economic or interest rate changes could impact future revenues.
  • Potential operational risks in managing its diverse business units including architectural, mortgage, and land development could affect profitability.

More from Press Releases

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026 Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026